For TMPRSS2-ERG, a well-known fusion in prostate cancer [4], the chimeric mRNA is typically a consequence of two intragenic breakpoints; indeed, we found 25 such cases in our cohort. The gene discussed is TMPRSS2; the disease is prostate cancer.